Alan B Lancz & Associates Inc. Makes New $228,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Alan B Lancz & Associates Inc. made a new investment of $228,000 in Zimmer Biomet Holdings, purchasing 2,500 shares of the medical equipment provider in the second quarter.
• Zimmer Biomet's recent quarterly earnings report showed an EPS of $2.07, exceeding analysts' expectations, along with a revenue of $2.08 billion for the quarter.
• The company announced a quarterly dividend of $0.24 per share, with an annualized yield of 0.9%, to be paid on October 31st.

Alan B Lancz & Associates Inc. purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 2,500 shares of the medical equipment provider's stock, valued at approximately $228,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Garde Capital Inc. acquired a new position in Zimmer Biomet in the 1st quarter worth $29,000. Washington Trust Advisors Inc. bought a new stake in shares of Zimmer Biomet in the first quarter valued at about $30,000. Columbia River Financial Group LLC acquired a new position in shares of Zimmer Biomet during the first quarter worth about $30,000. Accent Capital Management LLC bought a new position in shares of Zimmer Biomet during the first quarter worth about $35,000. Finally, Cullen Frost Bankers Inc. raised its position in Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider's stock valued at $37,000 after buying an additional 305 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $102.00 on Monday. The firm has a market capitalization of $20.21 billion, a P/E ratio of 24.82, a price-to-earnings-growth ratio of 2.35 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm's fifty day moving average price is $101.74 and its two-hundred day moving average price is $97.68. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ZBH shares. Stifel Nicolaus upped their price target on Zimmer Biomet from $115.00 to $118.00 and gave the stock a "buy" rating in a research report on Friday, September 19th. Evercore ISI cut their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 7th. Royal Bank Of Canada set a $111.00 target price on shares of Zimmer Biomet in a research report on Friday, October 10th. Rothschild Redb raised shares of Zimmer Biomet to a "strong-buy" rating in a research report on Thursday, September 18th. Finally, BTIG Research increased their price objective on shares of Zimmer Biomet from $118.00 to $122.00 and gave the stock a "buy" rating in a research note on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and an average price target of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.